Resmetirom API

Xi'an Faithful BioTech Co., Ltd: Your Trusted Resmetirom API Manufacturer & Supplier

Xi'an Faithful BioTech Co., Ltd supplies small molecule innovative drug intermediates, and Resmetirom API is our newly added core product. Since its establishment 8 years ago, we firmly believe in the principle of "small trust leads to big trust" and operate with integrity. Over the years, with high-quality products and services, our products have been exported to more than 20 countries overseas.

Resmetirom API Introduction

The Resmetirom API was launched in 2024 and was initially used to treat non-alcoholic steatohepatitis (NASH) in non cirrhotic patients with advanced liver fibrosis (F2-F3 stage). It is a first in class, orally active, selective thyroid hormone receptor beta (THR - β) agonist. The original powder is white to off white crystalline powder, and the Resmetirom API we supply comes from compliant manufacturers. The production process is fully controllable, and the final product has high purity and few impurities, making it a preferred choice for scientific research and production.

Specifications

Application area

1. It is the active ingredient of the world's first approved MASH therapeutic drug, directly used in the production of Resmetirom related preparations.
2. The core compound patent of Rui Si Mei Ti Luo is about to expire, and several domestic pharmaceutical companies have already laid out the development of generic drugs.
3. It can serve as a structural backbone for the development of innovative THR - β agonist drugs. It can also be used as a standard for quality research and impurity mass spectrometry analysis of MASH therapeutic drugs.
4. Used as a reagent in the mechanism research and cell experiments related to thyroid hormone receptors.

Main Advantages of Resmetirom API

Vast market prospects: The first approved MASH therapeutic drug on the market has a milestone significance.

Accurate therapeutic effect: The EC50 for THR - β receptors is 0.21 μ M, with selectivity about 18 times that of THR - α, and minimal side effects.

Patent window period: The patent expires in 2026 and can be used for the development of generic drugs.

If you need it ,you can click here

Why choose us

Assist you in seizing the opportunity of MASH raw materials: the patent is about to expire, and it is an excellent time for raw material suppliers to enter this field. We have deep cooperation with the factory to ensure stable supply.

Excellent Quality: Resmetirom API has high requirements for production processes, especially for isomer control and impurity mass spectrometry during the synthesis process. We cooperate with your factory to ensure product quality.

Quality Control

R&D Results

Packaging and Transportation

After-Sales Service

Qualification Certification

Exhibition

FAQ

Q1:When will the Resmetirom patent expire?

A1:Resmetirom's patent will expire in 2026.

Q2:What are the main adverse reactions?

A2:The most common side effects are gastrointestinal reactions, including diarrhea, nausea, vomiting, etc., which are usually mild to moderate and transient. Some patients may experience itching or dizziness.

Q3:What is the mechanism of action of Resmetirom?

A3:It is a highly selective THR - β agonist (EC50=0.21 μ M) that can bind to and activate the Calcitonin receptor β, promote hepatic fatty acid metabolism, reduce hepatic triglycerides, while avoiding activation of the THR - α receptor (which mainly mediates cardiac and skeletal side effects).

Contact US

We keep Resmetirom API in stock， pls tell me any time sales1@faithfulbio.com if you need a quotation.